Valproate Sodium

丙戊酸钠

Report date: 2026/03/26 20:00:17
NME

Base Information

Drug NameValproate Sodium
Drug Alias NameSodium Valproate
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlycogen synthase kinase-3 inhibitorsGamma-amino-N-butyrate transaminase inhibitors
TargetsGlycogen synthase kinase-3Gamma-amino-N-butyrate transaminase
Therapy Area/IndicationsBipolar DisorderFoodborne DiseasesSeizures +[6] 
Global Approved IndicationsBipolar DisorderSeizuresEpilepsy +[4] 
Approved Indications in ChinaNervous System Diseases
Original Approved Country/TerritoryJapan
Original Approved Date1974/05/24
Country/TerritoryCanadaUnited StatesEgypt +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu shengdi Medicine Co LtdKyowa Kirin Co LtdBgp Pharma Ulc +[8] 
Inactive CompaniesAbbvie Inc
Active IndicationsBipolar DisorderFoodborne DiseasesEpilepsy +[5] 
Inactive IndicationsSeizures

Other Information

ATC CodeN03AG01
Related LinksN/A